- VITT-like MGTS is linked to monoclonal antibodies targeting platelet factor 4.
- It resists standard anticoagulation therapy and features recurring blood clots with low levels of M proteins.
- The study documented distinct molecular characteristics.
- Treatment strategies beyond anticoagulation alone are recommended for these challenging cases.
- Testing for both anti-PF4 antibodies and M proteins is emphasized in unexplained chronic prothrombotic disorders.
Daily News
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
